Healthcare Valuation Multiples by Segment and Deal Size (Charts, January 2023 to October 2026)
The short answer. Size sets your multiple more than segment does. In Buckhead FMV's set of 187 U.S. healthcare services control deals announced Jan 2023 to Oct 2026, deals under $10 million sold at a median 2.8x EBITDA and deals above $200 million at 11.2x. All 187 deals sold at a median 0.88x revenue. The 68 deals with positive reported EBITDA sold at a median 9.6x EBITDA. Practice-level sales run lower still. Axia Growth's healthcare-sector closed sales, as of October 28, 2026, clear at 3.3x to 3.4x SDE below $2 million of earnings. Find your size band first. Then use the segment data to see where you fall inside that band.
Segment comes second because most segment medians rest on only a few deals. In Buckhead's data, ambulatory surgery centers (12.4x EBITDA, four deals) and outsourced services (11.6x) lead the service segments. Hospitals sit at 9.5x. Revenue multiples spread much wider than EBITDA multiples. They run from 0.11x for primary care practices to 2.8x for outsourced services because margins differ so much.
Data cutoffs: Buckhead FMV, deals announced through October 31, 2026. PitchBook, reported by Sikich in its Q3 2026 update, 2026 year to date as of that update. Axia Growth, closed sales as of October 28, 2026. FOCUS Investment Banking, 2026 benchmarks. Kaufman Hall, Q3 2026 report released October 13, 2026. Damodaran, NYU Stern, January 2026. CMS, 2024 national health spending. Figures labeled "our arithmetic" are derived from the cited source, and their assumptions are stated.
How to read the sources
Each source counts a different set of deals. A multiple means something only when you know its source, earnings basis and period. Do not set figures from two of these sources side by side as if they measure the same thing.
| Source | Population and cutoff | Basis | Use it for |
|---|---|---|---|
| Buckhead FMV | 187 U.S. control deals announced Jan 1, 2023 to Oct 31, 2026, each with a disclosed or court-approved price and primary-source financials. 68 of them report positive EBITDA | Median EV/revenue on all 187. Median EV/EBITDA on the 68 | Medians by segment, size and year, including hospitals and distressed sales |
| PitchBook, reported by Sikich | PitchBook healthcare M&A database, 2024 to 2026 year to date as of Sikich's Q3 2026 update | Median EV/EBITDA and EV/revenue | Market direction by year |
| Sikich | Sikich's indicative ranges by sub-sector and practice EBITDA, Q3 2026 | Banker ranges, EV/EBITDA | Bands for physician practices, ASCs, dental, urgent care, home health |
| Axia Growth | Closed small-business sales in the healthcare sector, as of Oct 28, 2026. Published on Axia's physician practice management page but covering the whole healthcare sector. 290 sales across six bands (our sum of Axia's published counts) | Median price to SDE below $2M of earnings, price to EBITDA at $2M and above | Lower middle market and practice-level pricing |
| FOCUS Investment Banking | 2026 healthcare dashboard and 2026 dermatology benchmarks | Banker ranges, EV/EBITDA | Specialty bands, size premium, buyer-type premium |
| Damodaran, NYU Stern | U.S. public companies by industry, January 2026 | EV/Sales and margins | Public-market reference by sub-sector |
Buckhead FMV method. Buckhead started with 215 U.S. healthcare transactions and kept the 187 that pass its screens. Every deal has a price and target financials from a primary source. Those sources are SEC 8-Ks, 10-Qs, 10-Ks and merger proxies, state certificate-of-need and transaction-notice filings in 12 states, bankruptcy court sale approvals, and Medicare cost reports for hospitals. The screen keeps control transactions, including deals that moved a buyer into majority control. It excludes minority stakes, physician syndications and deals where target revenue was estimated. Where a majority stake sold, Buckhead grosses EV up to 100%.
Buckhead shows EBITDA multiples only where EBITDA is positive. That leaves 68 of the 187 deals. The year chart and the segment chart below both draw on those 68 deals. Each year bar is a slice of them, and the segment bars cover only segments with enough deals to chart. Large and public deals report EBITDA far more often than small private ones. As a result, the 68 overrepresent larger transactions and every Buckhead EBITDA median carries that bias. Some prices include real estate and others do not. Cells with fewer than three observations are flagged, not dropped.
Size premium: 3.3x to 3.4x SDE at the bottom, 12.9x EBITDA above $10 million
Four sources measure size in four different ways. Read each ladder on its own. They do not join into one continuous scale.
| Ladder | Size measured by | Population and cutoff | Basis |
|---|---|---|---|
| Axia Growth | Seller earnings (SDE or EBITDA) | Healthcare-sector closed small-business sales, as of Oct 28, 2026 | Median price to SDE or EBITDA |
| Buckhead FMV | Deal value | U.S. control deals with primary-source financials, Jan 2023 to Oct 31, 2026 | Median EV/EBITDA and EV/revenue |
| Sikich | Practice EBITDA | Physician practices, Q3 2026 | Banker ranges |
| FOCUS | Practice revenue (EBITDA also qualifies for the top tier) | Dermatology practices, 2026 | Banker ranges |
Bands under $2M use seller discretionary earnings (SDE); larger bands use EBITDA.
Chart data
| Under $500K SDE (n=182) | 3.4 |
|---|---|
| $500K to $1M SDE (n=42) | 3.4 |
| $1M to $2M SDE (n=22) | 3.3 |
| $2M to $3M EBITDA (n=13) | 5.1 |
| $5M to $10M EBITDA (n=14) | 8.8 |
| $10M+ EBITDA (n=17) | 12.9 |
Source: Axia Growth, Physician Practice Management sales dataset
Chart source: Axia Growth, healthcare-sector closed small-business sales, as of October 28, 2026. The first three bars use SDE and the last three use EBITDA, so the step between the third and fourth bars partly reflects the change in basis. Axia publishes no $3M to $5M band.
Axia, SDE basis (owner's pay added back), as of Oct 28, 2026
| Seller SDE | n | Median price/SDE | Middle half (p25 to p75) |
|---|---|---|---|
| Under $500K | 182 | 3.4x | 2.7x to 4.2x |
| $500K to $1M | 42 | 3.4x | 2.5x to 4.4x |
| $1M to $2M | 22 | 3.3x | 2.7x to 7.5x |
Axia, EBITDA basis (market-rate pay deducted), as of Oct 28, 2026
| Seller EBITDA | n | Median price/EBITDA | Middle half (p25 to p75) |
|---|---|---|---|
| $2M to $3M | 13 | 5.1x | 3.1x to 10.9x |
| $3M to $5M | No band published | n/a | n/a |
| $5M to $10M | 14 | 8.8x | 3.4x to 10.7x |
| $10M+ | 17 | 12.9x | 9.4x to 18.5x |
Axia's footnote cites 4,554 closed small-business sales over $500K. That is its cross-sector database. The healthcare table holds 290 sales. Below $2 million of earnings, the SDE median stays flat at 3.3x to 3.4x across 246 sales, which is the most reliable figure here. The three EBITDA bands hold only 13 to 17 sales each, and the middle half of the $5M to $10M band runs from 3.4x to 10.7x. Read the climb from 5.1x to 12.9x as a direction, not a controlled size premium.
SDE is not EBITDA. SDE adds the owner's full compensation back to earnings. EBITDA deducts a market-rate salary for whoever replaces the owner. The size of that salary changes the converted multiple a lot. Our arithmetic, for a practice with $1.0 million of SDE sold at Axia's 3.4x median for a $3.4 million price:
| Assumed replacement salary (illustrative) | Implied EBITDA | Price as a multiple of EBITDA |
|---|---|---|
| $300,000 | $700,000 | 4.9x |
| $400,000 | $600,000 | 5.7x |
| $500,000 | $500,000 | 6.8x |
At this size, each $100,000 of replacement salary moves the converted multiple by 0.8 to 1.1 turns. The step gets bigger as the salary rises, because the EBITDA it is divided into shrinks. Set the salary from compensation survey data for your specialty and region. The BLS Health Care and Social Assistance page is the official source for sector wage data. Convert first, then compare the result with any EBITDA multiple on this page.
Who funds the small end. Most sub-$2 million SDE practices sell to individual physicians or small groups, and many of those buyers borrow. The SBA's 7(a) program is the agency's main small business loan program. The program sets a loan limit that can change, so buyers should confirm the current rule with their lender. That limit can restrict what a borrowing individual buyer can pay. It is one reason pricing in the bottom bands stays tight.
Buckhead FMV, by deal value, U.S. control deals announced Jan 2023 to Oct 31, 2026
| Deal value | Median EV/EBITDA (positive-EBITDA deals) | Median EV/revenue |
|---|---|---|
| Under $10M | 2.8x | 0.27x |
| Above $200M | 11.2x | 1.34x |
Buckhead publishes these two bands as the endpoints of its finding on scale. Small private deals report EBITDA less often, so the under-$10 million EBITDA median rests on fewer deals than its revenue median.
Sikich, physician practices by EBITDA, Q3 2026 (source)
| Practice EBITDA | EV/EBITDA |
|---|---|
| Under $1M | 5x to 7x |
| $1M to $3M | 7x to 9x |
| $3M to $5M | 9x to 11x |
| Above $5M | 11x to 13x |
FOCUS Investment Banking's 2026 dashboard says companies with more than $10 million in annual revenue "often see a 1.5x to 2x jump in valuation multiples as buyers price in infrastructure maturity and margin consistency." Treated as a multiplier on the multiple, that moves a business at 5x to 7.5x to 10x (our arithmetic). The result falls within Sikich's two middle bands.
FOCUS, dermatology by revenue, 2026 (source)
| Tier | Revenue | EV/EBITDA |
|---|---|---|
| Solo practice | Under $2M | 3x to 5x |
| Small group | $2M to $15M | 4x to 7x |
| Regional or mid-sized platform | $15M to $50M | 8x to 10x |
| Large integrated platform | $50M+ revenue or $10M+ EBITDA | 12x to 15x |
Buyer demand follows the same specialties. PESP's 2025 data, as reported by Becker's ASC Review, counts 148 PE deals involving outpatient care providers in 2025, 119 of them add-ons. Dermatology led with 24 deals, followed by eye care at 22 and oncology at 9. PESP builds its count from PitchBook and LevinPro HC and says the final count is likely an underestimate.
Decision table: your EBITDA band and what moves you up a band
| Practice EBITDA | Sikich range, Q3 2026 (physician practices) | Axia median, Oct 28, 2026 (healthcare-sector closed sales) | Most likely buyer | What gets you to the next band |
|---|---|---|---|---|
| Under $1M | 5x to 7x EBITDA | 3.4x SDE (convert before comparing) | Physician buyer, hospital, PE add-on | Remove owner dependence, close the books monthly, document payer contracts |
| $1M to $3M | 7x to 9x | 5.1x EBITDA at $2M to $3M (n=13) | PE add-on, regional group | Open a second site, bring associate providers to full production, centralize billing |
| $3M to $5M | 9x to 11x | No Axia band | PE add-on or small platform | Build management below the founder, add ancillary revenue, get financials ready for a QoE |
| $5M to $10M | 11x to 13x | 8.8x EBITDA (n=14) | PE platform, strategic | Run multiple sites, diversify payers, show you can integrate acquisitions repeatedly |
| $10M+ | 11x to 13x (Sikich's top band starts at $5M) | 12.9x EBITDA, middle half 9.4x to 18.5x (n=17) | Larger PE, strategic | Prove an add-on engine, build MSO infrastructure that scales |
The two multiple columns measure different things. Sikich gives banker ranges for physician practices. Axia gives medians of closed sales across the healthcare sector, including smaller private and non-physician businesses. That mix is why Axia runs lower in the middle bands.
Worked example 1: one practice, two benchmarks (our arithmetic). A physician practice with $2.0 million of normalized EBITDA.
| Benchmark | Multiple | Implied enterprise value |
|---|---|---|
| Sikich range, $1M to $3M EBITDA, Q3 2026 | 7x to 9x | $14.0M to $18.0M |
| Sikich midpoint | 8x | $16.0M |
| Axia median, $2M to $3M EBITDA, Oct 28, 2026 | 5.1x | $10.2M |
The Sikich midpoint ($16.0 million) and the Axia median ($10.2 million) are $5.8 million apart. That gap separates a banker range for physician practices from the median of 13 closed healthcare-sector sales. Process quality and buyer type decide where a deal lands. Run your own numbers in the practice valuation calculator.
Worked example 2: what a band move is worth (our arithmetic, Sikich Q3 2026 ranges). The same practice grows EBITDA from $2.0 million to $5.5 million by adding a second and third site.
| Stage | EBITDA | Sikich band | Implied EV | Band midpoint EV |
|---|---|---|---|---|
| Today | $2.0M | 7x to 9x | $14.0M to $18.0M | $16.0M at 8x |
| After growth | $5.5M | 11x to 13x | $60.5M to $71.5M | $66.0M at 12x |
EBITDA grows 2.75 times. Midpoint value grows from $16.0 million to $66.0 million, about 4.1 times, because the multiple expands along with earnings. The difference between those two growth rates is the size premium in dollars.
Worked example 3: cross-check a revenue multiple against margin (our arithmetic). A services business has $10.0 million of revenue and a 15% EBITDA margin, so it earns $1.5 million of EBITDA. At Buckhead's median of 0.88x revenue across all 187 deals, it would sell for $8.8 million, or 5.9x EBITDA. Any revenue multiple implies an EBITDA multiple. Divide the revenue multiple by your EBITDA margin (0.88 / 0.15 = 5.9) before you accept or reject an offer.
Segment spread: ASCs and outsourced services lead, hospitals at 9.5x
n = deals with positive disclosed EBITDA. Small samples; read as indicative.
Chart data
| HealthTech (n=3) | 31.4 |
|---|---|
| Specialty outpatient facilities (n=4) | 12.4 |
| Outsourced services (n=8) | 11.6 |
| Managed care (n=4) | 9.6 |
| Hospitals (n=26) | 9.5 |
| Home-based services (n=10) | 7.3 |
| Behavioral health (n=2) | 4.4 |
| Professional services (n=9) | 2.8 |
Chart source: Buckhead FMV, median EV/EBITDA by segment for the positive-EBITDA U.S. control deals announced January 2023 to October 31, 2026. Each bar shows its deal count and uses Buckhead's segment labels. The "specialty outpatient facilities" bar (12.4x, n=4) matches the figure Buckhead's summary gives for ambulatory surgery centers. Segments too small to chart are left out, so the bars add up to fewer than 68 deals. Our rule for every bar: a median built on fewer than ten deals shows direction and is not a benchmark. HealthTech (three deals) and behavioral health (two deals) fall well short of that.
| Segment (Buckhead FMV, Jan 2023 to Oct 31, 2026) | Median EV/EBITDA (positive-EBITDA deals) | Median EV/revenue (Buckhead summary) | How to read it |
|---|---|---|---|
| Ambulatory surgery centers | 12.4x (n=4) | 1.24x | Top service segment in Buckhead's summary, on four EBITDA deals |
| Outsourced services | 11.6x | 2.8x | Highest revenue multiple |
| Hospitals | 9.5x | 0.41x | Financials from Medicare cost reports and filings |
| Primary care practices | Not reported | 0.11x | Single-practice sales priced near asset value |
| HealthTech | 31.4x (n=3) | Not in Buckhead's summary | Too few deals to use as a price |
Revenue multiples follow margin. Outsourced services sell at 2.8x revenue and hospitals at 0.41x, yet their EBITDA multiples are only 2.1 turns apart (11.6x against 9.5x). The hospital simply converts much less of each revenue dollar into EBITDA. Growth, risk and capital intensity explain the remaining difference.
Chart data
| Outsourced services | 2.8 |
|---|---|
| HealthTech | 2.66 |
| Laboratories | 1.99 |
| Home-based services | 1.11 |
| Specialty outpatient facilities | 0.99 |
| Behavioral health | 0.63 |
| Hospitals | 0.41 |
| Managed care | 0.28 |
| Professional services | 0.25 |
Chart source: Buckhead FMV, median EV/revenue by segment, U.S. control deals announced January 2023 to October 31, 2026. More deals report revenue than EBITDA, so this chart covers more segments and more deals per bar. That is also why the specialty outpatient facilities bar here differs from the 1.24x ASC figure in Buckhead's summary. The two figures come from different cuts of Buckhead's data. Use the chart bar for the broad facility segment and 1.24x as Buckhead's ASC figure. Among charted segments, professional services is the lowest at 0.25x. The 0.11x primary care figure comes from Buckhead's written summary and is not charted, which is why the 0.11x low end in the table sits below every bar.
ASCs by type. Sikich's Q3 2026 update reports that the median ASC multiple reached 7.9x in 2025, the highest in at least eight years. Single-specialty centers trade at 5x to 8x, multispecialty centers at 6x to 10x and regional operators at 11x to 17x. Sikich marks ASCs as up in 2026 against 2025. Buckhead's 12.4x comes from four deals that disclosed EBITDA, which tilts toward larger operators, and it falls in Sikich's regional-operator band. A single-specialty center owner should anchor on 5x to 8x.
Primary care is the floor. Buckhead finds that hospital purchases of individual primary care practices, largely in West Virginia, cluster at 0.05x to 0.15x revenue. Buckhead reads that as payment for equipment and records, not goodwill. A primary care owner who wants goodwill paid needs a buyer who prices on EBITDA. That is the central decision in selling a physician practice.
Revenue growth does not set the multiple. The CMS National Health Expenditure fact sheet shows physician and clinical services spending grew 8.1% to $1,109.7 billion in 2024, and hospital spending grew 8.9% to $1,634.7 billion. CMS projects physician and clinical services spending to grow 5.5% a year on average from 2025 to 2034. Hospitals still sell at the low end of Buckhead's revenue range, because sector growth does not reach the margin line (see the Kaufman Hall data below). Buyers pay for converted earnings, not top-line growth.
Other sub-sector bands, Sikich Q3 2026 (source)
| Sub-sector | Indicative EV/EBITDA | 2026 vs 2025 | Sikich's evidence |
|---|---|---|---|
| Dental (DSOs) | Platforms 9x to 11x, add-ons 5x to 8x, practices 5x to 9x | Flat | Practice-level pricing steady for two years |
| Home health and hospice | Small agencies mid-single digits. Enhabit take-private at 10.2x | Down | Fewer closings. Buyers discount billing and compliance risk |
| Urgent care | 3x to 7x under $10M revenue, 6x to 11x at $10M to $50M | Not given | Banded by revenue |
| Hospitals (public comps as of June 30, 2026) | About 10x long-run average. HCA 8.5x, Community Health 7.5x, Ardent 6.1x | Flat | Public trading multiples |
| Platform vs add-on, same specialty | Platforms four to eight turns higher | Not given | The economics behind PE physician roll-ups |
Hospital sellers are getting bigger. Kaufman Hall's Q3 2026 report, released October 13, 2026, counts 16 hospital and health system deals announced in the quarter, the same number as Q3 2025. Total transacted revenue reached $8.2 billion, and Kaufman Hall puts average seller size near $586 million in annual revenue. Sikich reports the average Q3 seller had about $401 million of revenue a year earlier. Two Q3 deals were megamergers, the third consecutive quarter with megamerger activity. Kaufman Hall defines a megamerger as a deal where the smaller party has more than $1 billion in annual revenue. It says 2026 could set a record for these deals. Not-for-profits made up most of the acquirers, and divestitures accounted for nearly one-third of Q3 deals.
| Kaufman Hall hospital deal count | Announced transactions |
|---|---|
| Q1 2026 | 22 |
| Q2 2026 | 18 |
| Q3 2026 | 16 |
| 2026 through Q3 | 56 |
| Full year 2025 | 46, the lowest since tracking began in 2011 |
Quarterly counts as reported by Becker's Hospital Review. Weak seller economics drive the divestitures. Kaufman Hall puts the year-to-date hospital operating margin through August 2026 at 2.5% including allocations, with nearly 43% of hospitals operating at a loss. Non-labor expense per adjusted discharge rose 6% year to date against 2025. Supply expense rose 5% and drug expense 6%.
Year chart: 11.4x in 2023, 6.5x in 2025, 9.1x in 2026 through October
Buckhead attributes the 2025 dip to a smaller, more mid-market deal mix rather than broad repricing.
Chart data
| 2023 (n=12) | 11.4 |
|---|---|
| 2024 (n=28) | 9.7 |
| 2025 (n=15) | 6.5 |
| 2026 through Oct (n=13) | 9.1 |
Chart source: Buckhead FMV, median EV/EBITDA by year announced. The bars split the same 68 positive-EBITDA U.S. control deals used throughout this page, with 2026 covering deals announced through October 31.
Buckhead describes its yearly medians as moving within a band, not following a trend. It attributes the 2025 low to a smaller, more mid-market mix of disclosed deals, not a broad repricing. With distressed and bankruptcy sales excluded, Buckhead's January 2023 to October 2026 medians rise to 10.1x EBITDA and 0.98x revenue.
Chart data
| 2024 | 14.5 |
|---|---|
| 2025 | 13.0 |
| 2026 year to date | 11.6 |
Chart source: PitchBook median healthcare M&A EV/EBITDA, as reported in Sikich's Q3 2026 update. The 2026 bar is year to date as of that update.
Sikich reports PitchBook's trailing 12-month healthcare median at 12.7x and says it "still leads every sector." PitchBook's median EV/revenue held at 2.4x. Sikich also reports that the median PE-backed healthcare services company was bought at 13.6x EBITDA in 2025, against 13.5x in 2024. Over the same period, implied target EBITDA rose about 27% to roughly $33 million. Sponsors paid the same multiple for larger businesses. Entry leverage edged up to 5.2x.
| Year | Buckhead FMV median (positive-EBITDA U.S. control deals) | PitchBook median (reported by Sikich) | Gap in turns (our arithmetic) |
|---|---|---|---|
| 2023 | 11.4x | Not reported | n/a |
| 2024 | 9.7x | 14.5x | 4.8 |
| 2025 | 6.5x | 13.0x | 6.5 |
| 2026 YTD | 9.1x (through Oct 31) | 11.6x (as of Sikich's Q3 update) | 2.5 |
The gap moves around because the two populations change independently, and their 2026 cutoffs differ. PitchBook's database includes deals that never file public financials, many of them sponsor deals priced at platform multiples. Buckhead admits only deals with a verifiable price and financials. Use PitchBook to see which way the market is moving. Use Buckhead to see what verifiable control deals actually sold for.
Capital supply, Bain, 2025. Bain's Global Healthcare Private Equity Report 2026 estimates a record $191 billion of global healthcare PE deal value in 2025, above the 2021 peak. Bain's 2025 figures are actuals through November 30, 2025, annualized for the rest of the year. Its deal count excludes add-ons below $250 million.
| Bain 2025 estimate (global, annualized from Nov 30, 2025) | Deal value |
|---|---|
| All healthcare PE | $191B, a record |
| Biopharma | $80B, up from $55B in 2024 |
| Provider and related services | $62B, up 57% |
| Medtech | $33B, nearly double, on an estimated 88 deals |
| Healthcare IT in the provider segment | $32B, doubled |
Bain reports that North America accounts for more than 60% of global provider deal value. By count, PESP tracked 1,029 PE-backed healthcare deals in 2025: 151 leveraged buyouts, 664 add-ons and 214 growth investments. Bain's figures measure capital deployed and PESP's measure deal count. Neither shows the multiples paid.
Public comps: Damodaran EV/Sales from 0.46x to 7.92x
Chart data
| Drugs (Biotechnology) | 7.92 |
|---|---|
| Drugs (Pharmaceutical) | 6.24 |
| Healthcare IT | 5.31 |
| Healthcare Products | 4.76 |
| Total market | 3.97 |
| Hospitals/Healthcare Facilities | 1.69 |
| Healthcare Support Services | 0.46 |
Source: Damodaran, NYU Stern, Price and Enterprise Value to Sales, January 2026
Chart source: Damodaran, NYU Stern, EV/Sales by U.S. industry, January 2026, public companies only.
| Damodaran industry, U.S. public companies, Jan 2026 | Firms | EV/Sales | Gross margin | EBITDA margin | Pre-tax operating margin |
|---|---|---|---|---|---|
| Healthcare Support Services | 104 | 0.46x | 12.08% | 3.21% | 2.99% |
| Hospitals/Healthcare Facilities | 31 | 1.69x | 39.10% | 14.05% | 12.86% |
| Healthcare Products | 204 | 4.76x | 54.00% | 17.40% | 15.47% |
| Healthcare Information and Technology | 115 | 5.31x | 48.32% | 17.12% | 14.75% |
| Drugs (Pharmaceutical) | 228 | 6.24x | 71.73% | 31.24% | 29.54% |
| Drugs (Biotechnology) | 496 | 7.92x | 60.78% | 16.17% | 8.76% |
| Total Market | 5,994 | 3.97x | 37.76% | 14.39% | 12.75% |
EV/Sales and pre-tax operating margins come from Damodaran's January 2026 price-to-sales file. Gross and EBITDA margins come from his January 2026 margin file. Healthcare Support Services is a broad public group with thin margins: 12.08% gross, 3.21% EBITDA and 1.25% net. Treat its 0.46x as a floor for low-margin businesses, not a comp for an operating practice.
Compare margin with multiple. Hospitals earn a 14.05% EBITDA margin and trade at 1.69x sales. Healthcare IT earns 17.12% and trades at 5.31x. In our read, buyers pay software multiples only for software economics. A "tech-enabled" services company that earns services margins gets valued as a services company. Bain's $32 billion estimate for 2025 healthcare IT deal value in the provider segment shows where capital is flowing, not what multiples were paid.
4 adjustments between the headline multiple and your cash at close
- Buyer type. FOCUS's 2026 dashboard reports that corporate buyers in therapeutic and technology-driven sectors paid 20% to 40% higher multiples than sponsors on a like-for-like EBITDA basis. Applied to an 8x sponsor bid, that is 9.6x to 11.2x (our arithmetic).
- Escrow. SRS Acquiom's 2026 Deal Terms study covers 2025 deals. On deals with reps and warranties insurance (RWI), total escrow averaged 5.1% of transaction value, with a median of 2.8%. Without RWI it averaged 14.7%, with a median of 11.1%. The bid comparison below works through the dollar effect. Model your own in the deal proceeds calculator.
- Distress. In Buckhead's January 2023 to October 2026 set, the 22 distressed sales with reported revenue traded at a median 0.15x revenue. Most were hospitals sold out of the Steward, Prospect and other bankruptcies.
- Definitions. Some deal prices include real estate and others exclude it. The buyer applies the multiple to EBITDA after its own adjustments, not yours. Prepare with the QoE prep checklist and benchmark against multiples by sector and specialty.
Comparing a sponsor bid and a strategic bid on the same $2.0 million practice
A higher multiple does not always put more money in your hands at close. Our arithmetic below uses these assumptions:
- The practice from worked example 1 ($2.0 million of normalized EBITDA).
- The Sikich midpoint for the sponsor bid.
- The low end of FOCUS's 20% to 40% strategic premium. This assumes the practice is in a sector where that premium applies.
- SRS Acquiom's 2025 median escrow, applied to headline enterprise value as the transaction value.
- The sponsor buys RWI and the strategic does not. That split is our illustration, not a market rule.
| Line | Sponsor bid | Strategic bid |
|---|---|---|
| Normalized EBITDA | $2.0M | $2.0M |
| Multiple | 8.0x (Sikich midpoint, $1M to $3M band) | 9.6x (8.0x plus FOCUS's 20% low-end premium) |
| Headline enterprise value | $16,000,000 | $19,200,000 |
| RWI | Yes | No |
| Escrow at SRS Acquiom median | 2.8%: $448,000 | 11.1%: $2,131,200 |
| Value paid at close, before debt, fees and taxes | $15,552,000 | $17,068,800 |
The headline gap is $3.2 million. After escrow, the gap at close narrows to $1,516,800, and the strategic's $2.1 million holdback stays exposed to claims. At the top of FOCUS's range (11.2x, $22.4 million), the same 11.1% escrow holds back $2,486,400 and leaves $19,913,600 at close. Escrow can be calculated on a different base, such as equity value, and every deal sets its own terms. Ask each bidder the same questions before you compare offers:
- Which EBITDA figure does the multiple apply to, and which of your adjustments did they accept?
- Is real estate in or out of the price?
- How much is cash at close, how much is rollover equity, and how much is earnout?
- Who pays for RWI, and what escrow and survival period come with each structure?
- Is the bid priced as an add-on or as a platform?
Deal size, buyer type and any continuing role for referring physicians can raise antitrust, state transaction review and referral-law questions that affect timing and structure. Have your attorney review them early. Our healthcare M&A process guide and healthcare compliance due diligence guide explain where each issue comes up.
Checklist before you quote a multiple to a buyer or partner
- Name the source, population and cutoff of every multiple you cite.
- Confirm the earnings basis. SDE, adjusted EBITDA and reported EBITDA give different numbers for the same business.
- Convert SDE to EBITDA using a replacement salary from compensation data for your specialty and region.
- Divide any revenue multiple by your EBITDA margin to see the EBITDA multiple it implies.
- Match the band to your EBITDA after normalizing adjustments, not before.
- Check the deal count behind any median. Fewer than ten deals show a direction, not a price.
- Separate real estate from operating value before you apply a multiple.
- Model escrow, earnouts and rollover equity, then compare cash at close, not headline value.
- Look up any banker or firm advising you on FINRA BrokerCheck before you sign an engagement letter.
Questions owners ask about multiples by segment and size
What is the median EBITDA multiple for a healthcare services business in 2026?
The answer depends on which deals are counted. Buckhead FMV tracks U.S. control deals with primary-source financials. For its positive-EBITDA deals announced January 1 to October 31, 2026, the median is 9.1x. Across all 68 positive-EBITDA deals from January 2023 to October 2026, it is 9.6x. PitchBook data reported by Sikich in its Q3 2026 update shows 11.6x for 2026 year to date and 12.7x on a trailing 12-month basis. Buckhead's set includes hospitals and bankruptcy sales and admits only deals with verifiable financials. Those screens pull its median lower.
Which healthcare segment has the highest EBITDA multiple?
Among service segments with enough deals to read, Buckhead FMV's January 2023 to October 2026 data puts ambulatory surgery centers at 12.4x EBITDA (four deals) and outsourced services at 11.6x at the top. Hospitals sit at 9.5x. HealthTech posts a 31.4x median on Buckhead's segment chart, but that rests on three deals and is not a usable benchmark. Among U.S. public companies, Damodaran's January 2026 data shows Healthcare Information and Technology at 5.31x EV/Sales against 0.46x for Healthcare Support Services.
Why do Buckhead FMV and PitchBook medians differ so much?
They count different deals. Buckhead FMV screened 215 transactions down to 187 U.S. control deals. Each one has a disclosed or court-approved price and target financials from SEC filings, state transaction notices, bankruptcy approvals or Medicare cost reports. Only 68 of them report positive EBITDA. PitchBook draws on its own, wider healthcare M&A database, which includes many sponsor deals that never file public financials. By our arithmetic, PitchBook's median was 4.8 turns higher in 2024, 6.5 turns higher in 2025 and 2.5 turns higher in 2026 year to date. The 2026 cutoffs differ slightly.
Why does a small practice sell for 3x to 5x while platforms get 12x or more?
Small practices depend on the owner, draw fewer buyers and are priced on SDE, which adds the owner's pay back into earnings. Axia Growth's healthcare-sector closed sales, as of October 28, 2026, show medians of 3.3x to 3.4x SDE below $2 million of SDE. On EBITDA, the medians are 5.1x at $2 million to $3 million (13 sales), 8.8x at $5 million to $10 million (14 sales) and 12.9x above $10 million (17 sales). Those bands are small, so they show direction rather than a price. Platforms have management depth, central infrastructure and revenue from several sites, and a buyer can grow them with add-ons.
Do strategic buyers pay more than private equity for healthcare companies?
In therapeutic and technology-driven sectors, yes. FOCUS Investment Banking's 2026 dashboard reports that corporate buyers paid 20% to 40% higher multiples than financial sponsors on a like-for-like EBITDA basis. Private equity pays its own premium for platforms. Sikich's Q3 2026 update puts platforms four to eight turns above add-on practices in the same specialty. Compare cash at close, not headline multiples, because escrow terms differ by structure.
Did healthcare multiples fall in 2025?
Buckhead FMV's median for positive-EBITDA deals fell from 9.7x in 2024 to 6.5x in 2025, then returned to 9.1x for 2026 deals announced through October 31. Buckhead attributes the dip to a smaller, more mid-market deal mix, not a broad repricing. PitchBook's median, as reported by Sikich, moved from 14.5x in 2024 to 13x in 2025. Sikich also reports that PE-backed healthcare services companies were bought at a median 13.6x EBITDA in 2025, against 13.5x in 2024.
Sources
- Buckhead FMV, Healthcare Services M&A Valuation Multiples, deals announced January 2023 to October 31, 2026
- Sikich, Q3 2026 US Healthcare M&A Market Update and Year-End Outlook (reports PitchBook data)
- Axia Growth, healthcare-sector closed small-business sales by deal size, data as of October 28, 2026
- FOCUS Investment Banking, Healthcare EBITDA Multiples: 2026 Dashboard
- FOCUS Investment Banking, Dermatology Practice Valuation: 2026 Benchmarks
- Becker's ASC Review on PESP 2025 outpatient deal data
- Private Equity Stakeholder Project, Private Equity Healthcare Deals: 2025 in Review
- Kaufman Hall, Q3 2026 M&A Quarterly Activity Report press release, October 13, 2026
- Becker's Hospital Review on Kaufman Hall Q3 2026 data
- Bain & Company, Global Healthcare Private Equity Report 2026 press release, 2025 data annualized from November 30, 2025
- Bain & Company, New Models of Value Creation for Physician Groups, 2026
- Damodaran, NYU Stern, EV/Sales by industry, January 2026
- Damodaran, NYU Stern, margins by industry, January 2026
- SRS Acquiom, 2026 Deal Terms for M&A Escrows, 2025 deals
- CMS, National Health Expenditure fact sheet, 2024 data and 2025 to 2034 projections
- U.S. Small Business Administration, 7(a) loan program
- U.S. Bureau of Labor Statistics, Health Care and Social Assistance industry page
- FINRA BrokerCheck